Although these findings have not yet been validated in patients with type 1 myotonic dystrophy (DM1), they provide new avenues for exploring whether DPP-4 inhibitors could improve muscle function or slow the progression of fibrosis in DM1 patients. The gene discussed is DPP4; the disease is myotonic dystrophy type 1.